VIVS

VivoSim Labs, INC.

Nasdaq · CIK 1497253

Last close0.2
Daily change-0.01 (-4.76%)
10 Years gain-99.98%
Dividends TTM0
Dividend yield0.00%

Fundamental Analysis

VIVS · STANDARD

SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 0331

Screener
Fundamental
41.9
Momentum
100.0
Acceleration
100.0
Confidence
75.0
Annual Revenue16
Quarterly Revenue63
Annual CFO12
Balance SheetAvailable
RankingEligible

Score Breakdown

Growth0.0 / 25
Quality14.8 / 25
Capital Efficiency0.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics10.0 / 10
Forward Indicators0.0 / 5

Signals

Gross margin expansionGross margin improved by 4.0984 percentage points.
Operating leverageOperating margin improved by 147.5711 percentage points.
Net debt reductionNet debt declined versus the comparison period.

Warnings

Receivables anomaly · MEDIUMAccounts receivable growth is materially above revenue growth.
Heavy share dilution · HIGHDiluted share count increased 248.2034%.

Key Metrics

Revenue Growth TTM-10.66%OK
Revenue CAGR 3Y-29.26%OK
Gross Margin100%OK
Operating Margin-10,145.87%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Y7,940.63%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y248.2%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL

Financial History

PeriodRevenueGross ProfitOperating IncomeCFOFCFGross MarginOp MarginFCF MarginROICShares
2026 FY Mar 31, 2026$131,000.00$131,000.00-$11.49M-$10.83M-$10.83M100%-8,768.7%-8,264.89%n/a2.59M
2026 FY Mar 31, 2025$144,000.00$139,000.00-$12.62M-$9.46M-$9.47M96.53%-8,761.11%-6,579.17%n/a1.46M
2025 FY Mar 31, 2024$109,000.00$109,000.00-$15.09M-$14.65M-$14.70M100%-13,840.37%-13,481.65%-3,274.16%762,076
2024 FY Mar 31, 2023$370,000.00$370,000.00-$17.73M-$12.41M-$12.80M100%-4,792.16%-3,460.54%-1,793.53%8.71M
2023 FY Mar 31, 2022$1.50M$1.50M-$11.48M-$8.45M-$8.86M100%-765.27%-590.8%n/a8.7M

Formula Trace

MetricValueFormulaStatusSource
Revenue TTM$109,000.00sum latest 4 fiscal quarters RevenueOK0001193125-26-346820, 0001193125-25-269483
Revenue Growth TTM-10.66%Revenue_TTM / Revenue_TTM_1Y_ago - 1OK0001193125-26-346820, 0001193125-25-269483
Revenue CAGR 3Y-29.26%(Revenue_current / Revenue_3Y_ago)^(1/3) - 1OK0001193125-26-303316
Revenue CAGR 5Y-38.59%(Revenue_current / Revenue_5Y_ago)^(1/5) - 1OK0001193125-26-303316
Gross Profit CAGR 3Y-29.26%(GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1OK0001193125-26-303316
Operating Income Growthn/aOperatingIncome_current / OperatingIncome_prior_year - 1INSUFFICIENT_HISTORY0001193125-26-346820, 0001193125-25-269483
FCF Growthn/aFCF_current / FCF_prior_year - 1INSUFFICIENT_HISTORYderived
Revenue Growth Accelerationn/a0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3)INSUFFICIENT_HISTORYderived
Gross Profit Accelerationn/a0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3)INSUFFICIENT_HISTORYderived
Operating Income Accelerationn/a0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3)INSUFFICIENT_HISTORYderived
FCF Accelerationn/a0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3)INSUFFICIENT_HISTORYderived
Gross Margin100%Gross Profit / RevenueOK0001193125-26-346820, 0001193125-25-269483
Operating Margin-10,145.87%Operating Income / RevenueOK0001193125-26-346820, 0001193125-25-269483
Net Debt / CFOn/aNet Debt / CFONOT_MEANINGFUL0001193125-26-346820
Current Ratio1.7xCurrent Assets / Current LiabilitiesOKderived
Revenue per Diluted Share$0.02Revenue / Diluted SharesOK0001193125-26-346820, 0001193125-25-269483
SBC / FCFn/aSBC / FCFNOT_MEANINGFULderived
Dividend Payout Ration/aCash dividends paid / Net incomeNOT_MEANINGFUL0001193125-26-303316